RET and colorectal carcinoma: To minimize therapy related toxicity and improve anti-RET kinase response, it is worthwhile to evaluate the therapeutic index of currently available anti-RET tyrosine kinase inhibitors in the subset of CRC patients who express RET fusion kinase.